Form 4: Tango Therapeutics Director Malte Peters Receives Significant Equity Compensation Grants

Tango Therapeutics, Inc. Director Malte Peters was granted 6,250 restricted stock units and options to purchase 37,500 shares of common stock on June 5, 2025, as part of his compensation.

Summary

• Malte Peters, a Director of Tango Therapeutics, Inc. (TNGX), acquired 6,250 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 5, 2025.
• These RSUs were granted at a price of $0 and represent a contingent right to receive one share of Common Stock per RSU.
• The RSUs will vest in their entirety on the earlier of June 5, 2026, and the date of the next annual meeting of stockholders, subject to Mr. Peters' continuous service with the Issuer.
• Following this transaction, Mr. Peters beneficially owns 17,500 shares of Common Stock.
• Additionally, Mr. Peters was granted stock options to purchase 37,500 shares of Common Stock on June 5, 2025, with an exercise price of $3.51 per share.
• These options will vest in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, also subject to Mr. Peters' continuous service.
• The stock options have an expiration date of June 5, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of director and shareholder interests through equity compensation, suggesting confidence in the company's future. It's a routine compensation event, not indicative of major positive or negative news beyond that.

Positives

• The grant of equity compensation, including RSUs and stock options, aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedules for both the RSUs and stock options encourage the director's continued service and commitment to the company's success.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the Reporting Person's continuous service with Tango Therapeutics, Inc., meaning the full value is not realized if service ceases prematurely.
• The value of the stock options is dependent on the future market price of Tango Therapeutics' common stock exceeding the exercise price of $3.51 per share.

Future Outlook

The equity grants, with their vesting schedules extending into 2026 and 2035, indicate an expectation of continued service from Director Malte Peters and align his long-term incentives with the company's future performance and value creation.

Industry Context

This Form 4 filing reflects a common practice in the biotechnology or pharmaceutical industry, where equity compensation, including restricted stock units and stock options, is a standard component of executive and director remuneration. Such grants are used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success and stock performance of the company. Tango Therapeutics, as a clinical-stage biotechnology company, relies heavily on its leadership team, making such compensation critical for talent retention.

Comparison to Industry Standards

• The grant of RSUs and stock options to a director is a standard compensation mechanism across publicly traded companies, particularly in the biotechnology sector.
• While specific grant sizes vary based on company size, stage, and individual roles, the structure of time-based vesting (e.g., one year for options, one year or next annual meeting for RSUs) is typical for aligning director incentives with shareholder value over a defined period.
• Without specific peer company compensation data, a direct quantitative comparison is not feasible from this document alone, but the qualitative structure aligns with common industry practices for director equity compensation.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing shareholder value.

Next Steps

• Continued service of Malte Peters with Tango Therapeutics, Inc. to fulfill vesting conditions.
• Vesting of 6,250 Restricted Stock Units on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders.
• Monthly vesting of 37,500 stock options commencing July 5, 2025, over a one-year period.

Key Dates

Recommendation

Keywords

Tango Therapeutics, TNGX, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Malte Peters